Skip to content
1 min left
0% read
Patronus AI logo

Patronus AI

Technology Company
San Francisco, California, USA
Founded 2023
28

Powerful AI Evaluation and Security

Share:

Patronus AI

Patronus AI is the leading AI evaluation and optimization company. Our research-backed product enables AI engineers to optimize their agents, access powerful evaluation models, and automatically detect LLM system performance issues across 50+ modes. Leading technology companies and enterprises like AngelList, Etsy, and Pearson use Patronus AI to ship top-tier AI products.

Founded by machine learning experts from Meta, Patronus AI is on a mission to accelerate the world's adoption of generative AI. We are backed by Notable Capital, Lightspeed Venture Partners, Stanford University, Datadog, Gokul Rajaram, and leading software and AI executives.

Frequently Asked Questions About Patronus AI

Patronus AI is a finance company. Powerful AI Evaluation and Security

Patronus AI is the leading AI evaluation and optimization company. Our research-backed product enables AI engineers to optimize their agents, access powerful evaluation models, and automatically detect LLM system performance issues across 50+ modes. Leading technology companies and enterprises like.

Patronus AI has been operating since 2023. You can verify their legitimacy through their official website and social media presence.

Patronus AI operates in the finance sector of the cryptocurrency industry. Compare Patronus AI with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Patronus AI, research their track record (operating since 2023), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Patronus AI is based in San Francisco, California, USA, has been operating since 2023. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Patronus AI is based in San Francisco, California, USA, North America.

Patronus AI was founded in 2023. The company currently has 28 employees.

Patronus AI Details

Patronus AI Tags

More About Patronus AI

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m